In recognition and appreciation of the significant support, participation and guidance provided by HUPO's Industrial Advisory Board (IAB), one IAB member will be highlighted each month. We encourage you to connect with these companies directly for further information about their involvement in HUPO, and their products and services.
Pelago Bioscience is a CRO supporting all phases of drug discovery, with expertise in target engagement in biologically relevant assay systems. We believe that all drug discovery projects should know their target(s) before entering the clinic. To fulfill this mission, we utilize our patented core technology, CETSA® (Cellular Thermal Shift Assay), essential for early decision-making throughout the entire drug discovery pipeline.
CETSA measures the thermal stability of proteins in response to compound binding in a completely label-free manner. It offers multiple assay formats, from confirming target engagement and validating targets to generating hits for challenging targets and elucidating compound mechanisms of action. CETSA also excels in understanding the selectivity profile of compounds in biologically relevant models.
Pelago Bioscience services include among others:
Target Deconvolution with CETSA:
Uncover your drug candidate's interactions with targets through comprehensive, proteome-wide analysis. This combines CETSA with mass spectrometry, delivering unbiased results covering over 7,000 proteins without modifications to your compound or target proteins. Identify both on-target and off-target interactions in biologically relevant cell systems, providing crucial insights for target identification and mechanism of action studies.
Primary Screening with CETSA:
Accelerate your lead generation process by identifying high-quality chemical starting points with high-throughput screening. Benefit from rapid assay development, high-throughput screening for challenging targets, and identification of high-quality hits for further development, saving time and money while reducing attrition rates.
Hit Confirmation with CETSA:
Validate your selected target protein's binding to a compound in its native state. This service assesses compound binding without modifications to the protein or compound, ensuring accurate target engagement assessment and helping you prioritize promising drug candidates.
By partnering with Pelago Bioscience, you tap into:
Robust Target Engagement Assessment: Gain confidence in your drug targets, ensuring candidates engage with intended targets in a biologically relevant context.
Breakthroughs for Challenging Targets: Identify promising drug candidates for targets traditionally deemed "undruggable," unlocking new therapeutic possibilities.
Deep Mechanistic Insights: Understand the precise mechanisms of action of your compounds, illuminating interactions with targets and broader cellular pathways.
Comprehensive Selectivity Profiling: Assess compound specificity against potential off-targets in biologically relevant models, minimizing unwanted side effects.
Pelago Bioscience's team of seasoned scientists collaborates closely with you to deliver actionable insights, enabling confident asset prioritization in your drug discovery pipeline. Our expertise, over a decade of experience with more than 220 customers including leading pharmaceutical companies, and powerful CETSA technology make us your trusted partner in accelerating drug discovery.
.png)
